Novel SNARE Complex Polymorphisms Associated with Multiple Sclerosis: Signs of Synaptopathy in Multiple Sclerosis

Osman Özgür Yalın1, Tuba Gökdoğan Edgünlü2, Sevim Karakaş Çelik3, Ufuk Emre1, Taşkin Güneş4, Yüksel Erdal1, Aysun Eroğlu Ünal5

1Clinic of Neurology, İstanbul Training and Research Hospital, İstanbul, Turkey
2Department of Medical Biology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey
3Department of Molecular Biology and Genetic, Zonguldak Bülent Ecevit University Faculty of Science, Zonguldak, Turkey
4Clinic of Neurology, İstanbul Bahçelievler State Hospital, İstanbul, Turkey
5Department of Neurology, Tekirdağ Namık Kemal University School of Medicine, İstanbul, Turkey

Address for Correspondence: Yüksel Erdal, Clinic of Neurology, İstanbul Training and Research Hospital, İstanbul, Turkey
Phone: +90 212 459 60 00 e-mail: erdaluyuksel.355@hotmail.com ORCID: orcid.org/0000-0002-5338-3901
Received: 8 August 2017 Accepted: 24 December 2018 • DOI: 10.4274/balkanmedj.galenos.2018.2017.1034
Available at www.balkanmedicaljournal.org

Cite this article as: Yalın OÖ, Gökdoğan Edgünlü T, Karakaş Çelik S, Emre U, Güneş T, Erdal Y, et al. Novel SNARE Complex Polymorphisms Associated with Multiple Sclerosis: Signs of Synaptopathy in Multiple Sclerosis. Balkan Med J 2019;36:174-8

©Copyright 2019 by Trakya University Faculty of Medicine / The Balkan Medical Journal published by Galenos Publishing House.

Background: It is well known that axonal degeneration plays a role in disability in patients with multiple sclerosis, and synaptopathy has recently become an important issue.

Aims: To investigate the possible roles of selected synaptic and presynaptic membrane protein genetic polymorphisms (V AMP2, SNAP-25, synaptotagmin, and syntaxin 1A) in patients with multiple sclerosis.

Study Design: Case-control study.

Methods: A total of 123 patients with multiple sclerosis and 192 healthy controls were included. The functional polymorphisms of specific SNARE complex proteins (VAMP2, synaptotagmin XI, syntaxin 1A, and SNAP-25) were analyzed by polymerase chain reaction.

Results: Significant differences were detected in the genotype and allele distribution of 26-bp Ins/Del polymorphisms of VAMP2 between patients with multiple sclerosis and control subjects; Del/Del genotype and Del allele of VAMP2 were more frequent in patients with multiple sclerosis (p=0.011 and p=0.004, respectively). Similarly, Ddel polymorphism of SNAP-25 gene C/C genotype (p=0.059), syntaxin 1A T/C and C/C genotypes (p=0.005), and synaptotagmin XI gene C allele (p=0.001) were observed more frequently in patients with multiple sclerosis. CC, syntaxin rs1569061 1A gene for 33-bp promoter region TC haplotypes, and synaptotagmin XI gene were found to be associated with an increased risk for multiple sclerosis (p=0.012). Similarly, GC haplotype for rs3746544 of SNAP-25 gene and rs1051312 of SNAP-25 gene were associated with an increased risk for multiple sclerosis (p=0.022).

Conclusion: Genetic polymorphisms of SNARE complex proteins, which have critical roles in synaptic structure and communication, may play a role in the development of multiple sclerosis.

Keywords: Multiple sclerosis, polymorphism, SNARE proteins

Multiple sclerosis (MS) is an autoimmune, inflammatory disorder related to neuronal structure, and it is one of the prominent causes of young and middle-aged adult disability in the community. Several factors have been proposed for the development of MS, including genetic and environmental. Large population-based studies have shown that a high incidence of family history is possibly related to genetic factors (1). Specific genes associated with MS include the human leukocyte antigen system locus on chromosome 6, which serves as a major histocompatibility complex. The most consistent associations with MS have been found with DR15 and DQ6 alleles. Genome-wide association studies have also demonstrated several other susceptible genes besides the human leukocyte antigen loci (2,3).

Clinical presentation of MS can include various typical syndromes, including optic neuritis, pyramidal signs, and brainstem syndromes. However, consensus exists about the various clinical courses of the disease and the different types of MS (relapsing and progressive forms) based on clinical and pathological features. MS is traditionally characterized based on chronic inflammatory demyelinating lesions (4); however, recent studies have reported that axonal degeneration may be prominent in the beginning of the inflammation period of the disease (5,6). Axonal damage could be caused due to inflammation, vulnerability of demyelinated axons, or toxic effects of various complex biochemical reactions (7). Accumulating evidence indicates that axonal degeneration occurs not only as a consequence of inflammatory demyelination, but it can
also progress independently (5). Furthermore, axonal degeneration is assumed as one of the major determinants of permanent neurological impairment (8,9), and more recent studies have been focusing on the neurodegenerative component of the disease, which is believed to cause disability.

Experimental autoimmune encephalomyelitis is a useful model for the development of new therapies for MS (10). The levels of synapsins and syntaxins are decreased in experimental autoimmune encephalomyelitis. Synapsins and syntaxins are vesicle proteins that exhibit principal roles in exocytosis and in presynaptic terminals in the clinical symptoms of experimental autoimmune encephalomyelitis (11).

There is accumulated evidence suggesting the role of synaptopathy in MS. The term synaptopathy defines the alterations of the synaptic structure and function that have been associated in various neurological diseases, including epilepsy, autism, Alzheimer’s disease, and recently MS (12). Inflammatory-dependent synaptopathy is of particular interest because it is potentially reversible and may represent a novel therapeutic target for MS (12). Synapsins are neuronal phosphorylated proteins and play significant roles in vesicular trafficking in the synaptic region and are particularly related to cytoplasmic vesicle membranes (13). Syntaxin 1A protein is located in the presynaptic region and forms the SNARE complex with SNAP-25 and VAMP2; the SNARE complex is critical in neurotransmission (14). SNAP-25 plays a role in vesicle docking and fusion by mediating neurotransmitter secretion (15). SNAP-25 is present in the neurons and highly located in synaptic plasticity locations (16). Vesicle-associated SNARE complex components induce membrane fusion.

Recent studies have been focusing on factors that determine disability, and accumulated oxidative stressors are some of the proposed mechanisms. Therefore, we examined the synaptic vesicle protein (VAMP2), syntaxin 1A, and SNAP-25 genetic variants that are related to synaptogenesis and neuroplasticity in patients with MS.

**MATERIALS AND METHODS**

All patients voluntarily participated in the study, and consent was obtained from all participants. The Ethical Committee of the Istanbul Training and Research Hospital, Fatih, Istanbul approved this nonprofit study. The study was conducted between February 2014 and November 2015 in the neurology outpatient and inpatient clinics at the Istanbul Training and Research Hospital. Informed consents obtained from all participants. A total of 123 subjects with MS aged >18 years and 192 age-matched and healthy controls were included in this study. All the patients were evaluated and underwent a detailed neurologic examination by an experienced neurology specialist. After the final evaluation, the diagnosis of MS was based to the 2010 McDonald criteria (17). Finally, 87 patients with relapsing-remitting multiple sclerosis, 32 patients with secondary progressive multiple sclerosis, 4 patients with primary progressive multiple sclerosis, and 123 patients with MS were enrolled in this study. Those with clinically isolated syndrome, neuromyelitis optica, other demyelinating diseases, and doubtful cases were excluded.

First, we performed a literature search for identifying the associations of syntaxin 1A (intron 7, rs1569061), SNAP-25 (MnlI, rs3746544, and DdeI, rs1051312), VAMP2, and synaptotagmin XI gene polymorphisms in the MS population (Table 1) (14-16).

**Genotype analysis**

Blood samples were collected from patients and healthy volunteers in tubes containing ethylenediaminetetraacetic acid. Samples were stored at -20 °C until DNA isolation. DNA was isolated from whole blood using Pure Link Genomic DNA Purification Kit (Thermo Massachusetts, USA). Polymerase chain reaction was performed

**TABLE 1.** The PCR-RFLP evaluation method for VAMP2, synaptotagmin XI, syntaxin 1A, and SNAP-25 genes

| Gene | Polymorphism | Primers | Temperature of annealing | Restrictionendonuclease | PCR products |
|------|--------------|---------|--------------------------|------------------------|--------------|
| VAMP2 (14) | 26-bp Ins/Del polymorphism | P1, P2 | 57 °C | - | Ins allele: 116 bp Del allele: 90 bp |
| | | | | | T allele: 510 bp (3 repeats), 477 bp (2 repeats), 444 bp (1 repeat), C allele: 464 bp (3 repeats), 431 bp (2 repeats), 398 bp (1 repeat) |
| Synaptotagmin XI (Syt11) (14) | 33-bp repeats in promoter region | P3, P4 | 53 °C | HphI | |
| Syntaxin 1A (14) | Intron 7 (rs1569061) | P5, P6 | 57 °C | Tail | T allele: 312 bp C allele: 186, 126 bp |
| | | | | | |
| | | | | | |
| SNAP-25 (15,16) | MnII (rs3746544) | P7, P8 | 58 °C | MnI | T allele: 256, 5 bp G allele: 210, 46, 5 bp |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
using 2 mM dNTPs (Thermo Scientific R0242), 10 pmol of each primer, 1.5 mM MgCl₂, and 1×polymerase chain reaction buffer containing (NH₄)₂SO₄ and 2 U Taq DNA polymerase (Thermo Scientific 0402 Massachusetts, USA). Amplification was performed on an automated thermal cycler (Techne Flexigene, Cambridge, UK). A 100-bp DNA ladder (Thermo Scientific) was used as standard size for each gel lane. The gel was visualized under a UV visualizing system (Vilber Eberhardzell, Germany).

### Statistical analysis

Power analysis was performed considering the type I error rate as 0.05 for VAMP2 variable with 0.17 effect size, and the power was calculated as 0.775. Hardy–Weinberg equilibrium analysis was performed for patients and the control group, and the results were verified using the chi-square test and by estimating the expected genotypic frequencies based on the development of the square of the binomial. Baseline characteristics of the patients and control subjects were compared using t tests for continuous variables, and the results were presented as mean ± standard deviations, and χ² tests were used for categorical variables. Allelic and genotypic distributions between the study groups were compared using likelihood-ratio chi-square test or Fisher’s exact test. Linkage disequilibrium was tested, and haplotype analysis was performed to investigate the effects of the “linked” genes. Frequencies <0.03 were neglected. Statistical analysis was performed using SPSS 11.5 for Windows.

### RESULTS

This study included 123 patients with MS aged 18-65 years and 192 healthy controls. The patient group comprised 87 patients with relapsing-remitting multiple sclerosis, 32 patients with secondary progressive multiple sclerosis, and 4 subjects diagnosed with primary progressive multiple sclerosis. The mean age of the patients was 44.8±10.0 years, and that of the control group was 42.9±11.3 years. There was no significant difference in age and gender (p=0.268) between the groups. The demographic characteristics of the study subjects are presented in Table 2.

DNA samples collected from all participants were evaluated. We analyzed the alleles and genotypes of 26-bp Ins/Del polymorphisms of the VAMP2 gene, intron 7 rs1569061 polymorphism of the syntaxin 1A gene, MnlI (rs3746544) and Ddel (rs1051312) polymorphisms of the SNAP-25 gene, and 33-bp repeats in promoter regions of the synaptotagmin IX gene. Significant differences were observed in the genotype distribution of the 26-bp Del/Del polymorphisms of the VAMP2 and Del/Del genotypes, which were 3.194 (range 1.463-6.974) times more common in patients with MS (p=0.012). No difference was observed for the SNAP-25 gene MnlI (rs3746544) polymorphism; however, Ddel (rs1051312) polymorphism C/C genotype was more frequently found in patients with MS [odds ratio (OR) (95% confidence interval (CI) 2.137 (1.075-4.248), p=0.059]. Polymorphisms of intron 7 rs1569061 syntaxin 1A gene T/C and C/C genotypes were observed significantly more frequently in the MS group. This difference was also observed in patients with relapsing-remitting multiple sclerosis [OR (95% CI) 2.127 (1.225-3.693) and 2.544 (1.366-4.738), respectively, p=0.05]. The results of the genotypes of VAMP2, SNAP-25, and syntaxin 1A gene variants are presented in Table 3.

We investigated the alleles of VAMP2, SNAP-25, syntaxin 1A, and synaptotagmin IX gene polymorphisms. Del allele of VAMP2 gene was observed 1.688 (range 1.183-2.407) times more frequently in patients with MS (p=0.004); similarly, the C allele of synaptotagmin IX gene was observed more frequently in patients with MS [OR (95% CI) 1.711 (1.238-2.363), p=0.001]. Allelic distributions of other genes were similar for both groups. The results are presented in Table 4.

Finally, haplotype analysis revealed significant differences between the study groups. We observed that TC and CC haplotypes for...
rs1569061 syntaxin 1A gene and the 33-bp promoter region of the synaptotagmin XI gene could be risk factors for the development of MS [OR (95% CI) 1.686 (1.049-2.710) and 1.588 (1.041-2.420), p=0.012, respectively]. Similarly, the GC haplotype of the SNAP-25 MnlI gene and the SNAP-25 Ddel gene was associated with a 1.948-fold [OR (95% CI) 1.948 (1.251-3.033), p=0.022] increased risk of MS development. Results of the haplotype analysis are presented in Table 5.

The data of patients with secondary progressive multiple sclerosis and primary progressive multiple sclerosis were not analyzed separately because of the small number of patients.

### TABLE 4. Alleles of VAMP2, SNAP-25, and syntaxin 1A genes

| Allele          | Control (n=192) | Cases (n=123) | χ² p value | OR (95% CI) |
|-----------------|-----------------|---------------|------------|-------------|
| VAMP2 Ins       | 295 (76.8%)     | 163 (66.3%)   | p=0.004    | 1           |
| VAMP2 Del       | 89 (23.2%)      | 83 (33.7%)    | p=0.097    | 1           |
| SNAP-25 MnlI T  | 134 (34.9%)     | 102 (41.5%)   | p=0.011    | 1.547 (1.103-2.171) |
| SNAP-25 Ddel C  | 111 (28.9%)     | 95 (38.6%)    | p=0.988    | 1           |
| Syntaxin 1A T   | 186 (48.4%)     | 119 (48.4%)   | p=0.001    | 1           |
| Syntaxin 1A C   | 198 (51.6%)     | 127 (51.6%)   |             | 1.686 (1.049-2.710) |
| SNAP-25 Mnll GC | 151 (61.4%)     | 114 (46.3%)   |             | 1.588 (1.041-2.420) |
| SNAP-25 Ddel GC | 155 (54.1%)     | 114 (46.3%)   |             | 1.711 (1.238-2.363) |

CI: confidence interval; OR: odds ratio

### TABLE 5. Haplotype distributions of Syntaxin 1A and SNAP-25 genes

| Allele          | Control (n=192) | Cases (n=123) | χ² p value | OR (95% CI) |
|-----------------|-----------------|---------------|------------|-------------|
| Syntaxin 1A Synaptotagmin |                |               |            |             |
| TT              | 126 (32.8%)     | 66 (26.8%)    | p=0.012    | 0.890 (0.565-1.401) |
| CT              | 103 (26.8%)     | 48 (19.5%)    |             | 1.686 (1.049-2.710) |
| CC              | 95 (24.7%)      | 79 (32.1%)    |             | 1.588 (1.041-2.420) |
| SNAP-25 Mnll / SNAP-25 Ddel |         |               |            |             |
| TT              | 192 (50.0%)     | 106           | p=0.022    | 1.006 (0.651-1.554) |
| CT              | 81 (21.1%)      | 45 (18.3%)    |             | 1.187 (0.740-1.904) |
| CC              | 58 (15.1%)      | 38 (15.4%)    |             | 1.948 (1.251-3.033) |

CI: confidence interval; OR: odds ratio

**DISCUSSION**

We evaluated the polymorphisms of the SNARE complex proteins (VAMP2, SNAP-25, syntaxin 1A, and synaptotagmin XI) in patients with MS. To our knowledge, this is the first study to evaluate the associations between the SNARE complex genetic polymorphisms and MS. We found associations between MS and VAMP2 Del/Del, SNAP-25 Ddel/C/C, and syntaxin1A T/C and C/C genotypes. VAMP2 gene Ddel allele and C allele of synaptotagmin XI were also associated with an increased risk of developing MS. Moreover, syntaxin1A/synaptotagmin XI genes, TC and CC haplotypes, and SNAP-25 Mnll/SNAP-25 Ddel GC haplotype were found to be associated with an increased risk of MS development.

It has recently been proposed that not only myelin but also synapses are involved in the early phases of MS development (18,19). Initial autopsy studies of patients with relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, and secondary progressive multiple sclerosis have reported decreased levels of synaptic proteins, including synaptotagmin and synaptophysin. Synaptophysin is a presynaptic vesicle protein that plays a role in synaptic vesicle release (20,21).

Evidence of early synaptopathy in MS has been documented in experimental and autopsy studies (12,21,22). Earlier studies investigating synapsin III genetic polymorphisms in MS have reported conflicting results (23-25). SNAP-25 proteins exist in all parts of the brain tissue. There is accumulated evidence showing that SNARE proteins are widely present in the brain. SNARE complex proteins play a crucial role in providing and sustaining healthy synaptic structure and functions. Genetic polymorphisms of associated proteins have been found to be associated with several central nervous system disorders (26-29). Synapses are morphologically dynamic structures and dysfunctions can be repaired and new synapses can be formed.

This dynamic structure of synapses could provide novel treatment strategies (12). The SNARE-related genes may have a role in structural expression or may contribute to neurological disorders. As a part of the SNARE complex, synaptotagmins are extensively found in the brain and have important roles in membrane trafficking and synaptic plasticity. Synaptotagmin polymorphisms have been well studied in the etiology of epilepsy (29).

Synapsins are composed of a group of specific neuroproteins. Synapsins are responsible for trafficking of synaptic vesicles from presynaptic terminals, particularly related to the cytoplasmic surface (30). They play a crucial role in synaptogenesis and early axonal development. Although SNAP-I and -II are believed to be associated with neuronal development, SNAP-III was recently discovered and has unique functions in neurotransmitter regulation in mature neurons (31). The role of SNAP-III polymorphisms has been investigated in schizophrenia, Alzheimer’s disease, and MS (31-34). Liquori et al. (31) reported an inverse association between SNAP-III promoter gene polymorphism and MS. SNAP-25 is another SNARE complex protein that has been investigated in psychiatric and neurological diseases. SNAP-25 is believed to play a role in regulating synaptic homeostasis (35). In particular,
syntxin 1A has a role in the synaptic exocytosis process and neuronal plasticity (36). Although the roles of presynaptic and synaptic membrane proteins have been well investigated, their precise roles in the healthy brain and in neurological disorders still remain unclear.

This study has certain limitations; it is not population-based and may not represent the wider population. The sample size of the study group was relatively small to assess the secondary progressive multiple sclerosis and primary progressive multiple sclerosis genetic associations and the correlations with disability scores. We are planning to investigate a broader series of relationship of genetic polymorphisms in our future studies. This study has demonstrated novel genetic associations in MS related to synaptopathy. We believe that future functional and clinical studies on the gene expressions of SNARE complex proteins are needed. Our findings should be confirmed by further studies in different populations.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: No financial disclosure was declared by the authors.

REFERENCES

1. Lill CM. Recent advances and future challenges in the genetics of multiple sclerosis. Front Neurol 2014;14:130.

2. Compston A, Coles A. Multiple Sclerosis. Lancet 2002;6:1221-31.

3. Baranzini SE. Revealing the genetic basis of multiple sclerosis: are we there yet? Curr Opin Genet Dev 2011;21:317-24.

4. Charcot JM. Leçons sur les maladies du système nerveux faiées a la Salpêtrière. Paris: A. Delahaye; 1880.

5. Frischer JM, Bramow S, Dal-Bianco A, Lucchinietti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175-89.

6. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp Neurol 2010;225:2-8.

7. Owens T. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurosci 2003;16:259-65.

8. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469-77.

9. Lee YJ, Taghian K, Petraitos S. Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability? Acta Neuropathol Commun 2014;2:97.

10. Mix E, Meyer-Riemente H, Hartung HP, Zettl UK. Animal models of multiple sclerosis—potential and limitations. Prog Neurobiol 2010;92:386-404.

11. Srivastava P, Mujitba MA, Singhal M. Gene and Cytokines Expression of Multiple Sclerosis and Its Therapeutic Regimen: A Systemic Review. Int J Drug Dev Res 2012;4:55-66.

12. Mandolesi G, Gentile A, Musella A, Fresegna D, Radel M, Wettl WC, et al. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat Rev Neurol 2015;11:711-24.

13. Gitler D, Takagishi Y, Feng J, Ren Y, Rodriguez RM, Wetsel WC, et al. Different presynaptic roles of synapsins at excitatory and inhibitory synapses. J Neurosci 2004;24:11368-80.

14. Bennett MK, Calakos N, Scheller RH. Syntaxin: a synaptic protein implicated in docking of synaptic vesicles at presynaptic active zones. Science 1992;257:255-8.

15. Söllner TH. Regulated exocytosis and SNARE function (Review). Mol Membr Biol 2003;20:209-20.

16. Barr CL, Feng Y, Wigg K, Bloom S, Roberts W, Malone M, et al. Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. Mol Psychiatry 2000;5:405-9.

17. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.

18. Musella A, Mandolesi G, Mori F, Gentile A, Centonze D. Linking synaptopathy and gray matter damage in multiple sclerosis. Mult Scler 2016;22:146-9.

19. Jürgens T, Jafari M, Kreutzfeldt M, Bahn E, Brück W, Kerschensteiner M. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain 2016;139:39-46.

20. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006;67:960-7.

21. Dutta R, Chang A, Doud MK, Kidd GJ, Ribaufo MV, Young EA, et al. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 2011;69:445-54.

22. Vercellino M, Merola A, Piancettino C, Votta B, Capello E, Mancardi GL, et al. Altered glutamate receptor in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neurol Exp Neurol 2007;66:723-9.

23. Liguori M, Cittadella R, Manna I, Valentino P, La Russa A, Serra P, et al. Association between Synapsin III gene promoter polymorphisms and multiple sclerosis. J Neurol 2004;251:165-70.

24. Akkad DA, Gödde R, Epplen JT. No association between synapsin III gene promoter polymorphisms and multiple sclerosis in German patients. J Neurol 2006;253:1365-6.

25. Otaseg D, Zariarain O, Castillo-Trivino T, Aransay A, Ruiz-Martinez J, Olaskoaga A, et al. Association between synapsin III gene promoter SNPs and multiple sclerosis in Basque patients. Mult Scler 2009;15:124-8.

26. Guerini FR, Bolognesi E, Chiappelli M, Mancia S, Ghezzo A, Agliardi C, et al. SNAP-25 single nucleotide polymorphisms are associated with hyperactivity in autism spectrum disorders. Pharmacol Res 2011;64:283-8.

27. Barakauskas VE, Beasley CL, Barr AM, Ypsilanti AR, Li HY, Thornton AE, et al. A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia. Neuropsychopharmacol 2010;35:1226-38.

28. Gylls KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM. Synaptic changes in Alzheimer's disease increased amyloid-β and gliosis in surviving terminals is accompanied by decreased P95 fluorescence. Am J Pathol 2004;165:1809-17.

29. Yilmaz M, Edgunlu TG, Yilmaz N, Cetin ES, Celik SK, Emir GK, et al. Genetic variants of synaptic vesicle and presynaptic plasma membrane proteins in idiopathic generalized epilepsy. J Recept Sig Transduct Res 2014;34:38-43.

30. De Camilli P, Harris SM Jr, Huttner WB, Greengard P. Synapsin I (Protein I), a nerve terminal-specific phosphoprotein. II. Its specific association with synaptic vesicles demonstrated by immunocytochemistry in agarose-embedded synaptosomes. J Cell Biol 1983;96:1355-73.

31. Liguori M, Cittadella R, Manna I, Valentino P, La Russa A, Serra P, et al. Association between Synapsin III gene promoter polymorphisms and multiple sclerosis. J Neurol 2004;251:165-70.

32. Ohmori O, Shinkai T, Hori I, Kojima H, Nakamura J. Synapsin III gene polymorphisms and schizophrenia. Neurosci Lett 2000;279:125-7.

33. Tsai MT, Hung CC, Tsai CY, Liu MY, Su YC, Chen YH, et al. Mutation analysis of synapsin III gene in schizophrenia. Am J Med Genet 2002;114:79-83.

34. Edgunlu TG, Özge A, Yalın OO, Kul S, Erdal ME. Genetic variants of Synaptic Vesicle and presynaptic plasma membrane proteins in idiopathic generalized epilepsy. Int J Mol Sci 2015;16:1670-170.

35. Corradini I, Verderio C, Sala M, Wilson MC, Matteoli M. SNAP-25 in neuropsychiatric disorders. Pharmacol Res 2011;64:283-8.

36. Ullrich A, Böhme MA, Schönhütter J, Depner H, Sigrist SJ, Noé F. Dynamical Organization of Syntaxin-1A at the Presynaptic Active Zone. PLoS Comput Biol 2015;11:1004407.